Stimvia, a Czech Republic-based neuromodulation company focused on transforming the treatment of bladder dysfunction, has appointed Russ Mably as CEO. Mably will lead the company through its next phase of international growth, expanding access to the firm’s personalised neuromodulation platform and advancing its mission to improve outcomes for patients worldwide.
Under Mably’s leadership, the company will focus on expanding global market access, strengthening strategic partnerships and accelerating commercialisation.
Mably brings more than 20 years of experience leading and scaling international medical technology businesses, most recently as CEO of Celox Medical.
Founder Lukas Doskocil will transition to the role of founder & chief product officer, where he will lead product strategy, technology development and the advancement of Stimvia’s next-generation neuromodulation platform.
